



Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

OPEN ACCESS

Edited and reviewed by:

Massimo Broggini, Mario Negri Pharmacological Research Institute (IRCCS), Italy

*Correspondence:

Jianbin Li lijianbin@msn.com Zhenxiang Li lizx0108@163.com

Specialty section:

This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology

Received: 15 July 2020 Accepted: 10 September 2020 Published: 20 November 2020

Citation:

Shi J, Zhang Y, Wang J, Li J and Li Z (2020) Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. Front. Oncol. 10:583499. doi: 10.3389/fonc.2020.583499 Jingzhen Shi^{1,2,3}, Yingjie Zhang^{2,3}, Jinzhi Wang^{2,3}, Jianbin Li^{2,3*} and Zhenxiang Li^{3*}

¹ School of Medicine, Shandong University, Jinan, China, ² Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China, ³ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

Keywords: patient-derived xenograft, esophageal squamous cell carcinoma, anlotinib, chemoradiotherapy, anti-angiogenesis

A Corrigendum on

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

by Shi, J., Zhang, Y., Wang, J., Li, J. and Li, Z. (2020). Front. Oncol. 10:995. doi: 10.3389/fonc.2020.00995

In the original article, there was a mistake in **Figure 1** and **Table 2** as published. Duplicated panels were contained in **Figure 1** due to author error. The authors provided a modified **Figure 1** during the review process. The data of the pre-experiment were misplaced in **Table 2** and submitted after the proofs due to author error. The corrected **Figure 1** and **Table 2** appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Shi, Zhang, Wang, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

1



FIGURE 1 | Histological section (H&E) presented that the esophageal patient tissue (P0) was consistent with the series passages (P1, P2, P3, and P4) in the SCID mice (×200).

TABLE 2 The detailed data of tumor volume and body weig	ht.
---	-----

Tumor volume (mm ³)	Control group	RT	RT+DDP	RT+Anlotinib	RT+DDP+Anlotinib
Initial	266.64 ± 37.05	243.4 ± 31.38	252.61 ± 60.13	260.90 ± 43.67	267.24 ± 51.13
Final	343.51 ± 29.22	188.54 ± 40.04	150.31 ± 15.87	144.29 ± 15.05	121.02 ± 25.72
Changing	77.06 ± 32.90	-54.95 ± 39.63	-102.31 ± 46.44	-116.61 ± 45.17	-146.23 ± 48.59
Initial	187.52 \pm 62.04	171.5 ± 31.30	185.45 ± 44.30	178.06 ± 40.02	181.31 ± 15.67
Final	$246.07\ \pm\ 109.69$	116.3 ± 25.17	133.11 \pm 53.32	119.17 \pm 30.60	71.79 ± 5.88
Changing	58.55 ± 64.42	-55.11 ± 22.68	-52.34 ± 55.52	-58.89 ± 38.21	-109.52 ± 18.05
Initial	$267.39\ \pm\ 28.18$	265.4 ± 57.22	267.33 ± 53.02	256.01 ± 30.76	262.82 ± 29.66
Final	648.68 ± 222.59	130.7 ± 57.33	161.87 ± 45.37	124.46 \pm 38.87	70.89 ± 15.46
Changing	381.33 ± 251.804	-134 ± 17.26	-105.46 ± 13.90	-131.54 ± 35.45	-191.93 ± 42.70
Body weight (g)	Control group	RT	RT+DDP	RT+Anlotinib	RT+DDP+Anlotinib
Initial	25.92 ± 22.15	24.85 ± 2.06	26.3 ± 41.20	24.7 ± 81.34	24.29 ± 1.57
Final	25.99 ± 0.50	24.77 ± 2.30	25.9 ± 62.02	23.9 ± 12.47	23.45 ± 2.27
Changing	0.06 ± 2.53	-0.08 ± 0.73	-0.88 ± 1.84	-0.87 ± 2.56	-0.83 ± 1.39
Initial	22.68 ± 1.79	22.25 ± 0.84	22.66 ± 1.08	22.32 ± 1.48	22.71 ± 2.71
Final	24.07 ± 0.77	23.35 ± 1.82	23.03 ± 1.01	22.05 ± 1.87	23.29 ± 1.47
Changing	1.60 ± 1.23	1.10 ± 1.21	0.37 ± 0.84	-0.27 ± 1.17	0.57 ± 1.46
initial	22.00 ± 2.54	21.23 ± 2.77	20.86 ± 2.92	21.99 ± 2.70	22.05 ± 2.58
Final	24.21 ± 1.31	22.10 ± 1.30	22.86 ± 0.97	22.84 ± 1.07	22.69 ± 0.95
Changing	$2.21~\pm~2.33$	1.16 ± 1.72	2.00 ± 3.17	0.85 ± 3.15	0.64 ± 3.11
	Tumor volume (mm³) Initial Final Changing Changing Initial Final Changing Initial	Tumor volume (mm³)Control groupInitial 266.64 ± 37.05 Final 343.51 ± 29.22 Changing 77.06 ± 32.90 Initial 187.52 ± 62.04 Final 246.07 ± 109.69 Changing 58.55 ± 64.42 Initial 267.39 ± 28.18 Final 648.68 ± 222.59 Changing 381.33 ± 251.804 Body weight (g)Control groupInitial 25.92 ± 22.15 Final 25.99 ± 0.50 Changing 0.06 ± 2.53 Initial 22.68 ± 1.79 Final 24.07 ± 0.77 Changing 1.60 ± 1.23 initial 22.00 ± 2.54 Final 22.00 ± 2.54 Final 24.21 ± 1.31 Changing 2.21 ± 2.33	Tumor volume (mm³)Control groupRTInitial 266.64 ± 37.05 243.4 ± 31.38 Final 343.51 ± 29.22 188.54 ± 40.04 Changing 77.06 ± 32.90 -54.95 ± 39.63 Initial 187.52 ± 62.04 171.5 ± 31.30 Final 246.07 ± 109.69 116.3 ± 25.17 Changing 58.55 ± 64.42 -55.11 ± 22.68 Initial 267.39 ± 28.18 265.4 ± 57.22 Final 648.68 ± 222.59 130.7 ± 57.33 Changing 381.33 ± 251.804 -134 ± 17.26 Body weight (g)Control groupRTInitial 25.92 ± 22.15 24.85 ± 2.06 Final 25.99 ± 0.50 24.77 ± 2.30 Changing 0.06 ± 2.53 -0.08 ± 0.73 Initial 22.68 ± 1.79 22.25 ± 0.84 Final 24.07 ± 0.77 23.35 ± 1.82 Changing 1.60 ± 1.23 1.10 ± 1.21 initial 22.00 ± 2.54 21.23 ± 2.77 Final 24.21 ± 1.31 22.10 ± 1.30 Changing 2.21 ± 2.33 1.16 ± 1.72	Tumor volume (mm³)Control groupRTRT+DDPInitial 266.64 ± 37.05 243.4 ± 31.38 252.61 ± 60.13 Final 343.51 ± 29.22 188.54 ± 40.04 150.31 ± 15.87 Changing 77.06 ± 32.90 -54.95 ± 39.63 -102.31 ± 46.44 Initial 187.52 ± 62.04 171.5 ± 31.30 185.45 ± 44.30 Final 246.07 ± 109.69 116.3 ± 25.17 133.11 ± 53.32 Changing 58.55 ± 64.42 -55.11 ± 22.68 -52.34 ± 55.52 Initial 267.39 ± 28.18 265.4 ± 57.22 267.33 ± 53.02 Final 648.68 ± 222.59 130.7 ± 57.33 161.87 ± 45.37 Changing 381.33 ± 251.804 -134 ± 17.26 -105.46 ± 13.90 Max 25.92 ± 22.15 24.85 ± 2.06 26.3 ± 41.20 Final 25.92 ± 0.50 24.77 ± 2.30 25.99 ± 62.02 Changing 0.06 ± 2.53 -0.08 ± 0.73 -0.88 ± 1.84 Initial 22.68 ± 1.79 22.25 ± 0.84 22.66 ± 1.08 Final 24.07 ± 0.77 23.35 ± 1.82 23.03 ± 1.01 Changing 1.60 ± 1.23 1.10 ± 1.21 0.37 ± 0.84 Initial 22.00 ± 2.54 21.23 ± 2.77 20.86 ± 2.92 Final 24.21 ± 1.31 22.10 ± 1.30 22.86 ± 0.97 Changing 1.60 ± 1.23 1.10 ± 1.21 0.37 ± 0.84 Initial 22.01 ± 2.33 1.16 ± 1.72 2.00 ± 3.17	Tumor volume (nm³)Control groupRTRT+DDPRT+AhlotinibInitial266.64 ± 37.05243.4 ± 31.38252.61 ± 60.13260.90 ± 43.67Final343.51 ± 29.22188.54 ± 40.04150.31 ± 15.87144.29 ± 15.05Changing77.06 ± 32.90-54.95 ± 39.63-102.31 ± 46.44-116.61 ± 45.17Initial187.52 ± 62.04171.5 ± 31.30185.45 ± 44.30178.06 ± 40.02Final246.07 ± 109.69116.3 ± 25.17133.11 ± 53.32119.17 ± 30.60Changing58.55 ± 64.42-55.11 ± 22.68-52.34 ± 55.52-58.89 ± 38.21Initial267.39 ± 28.18265.4 ± 57.22267.33 ± 53.02256.01 ± 30.76Final648.68 ± 222.59130.7 ± 57.33161.87 ± 45.37124.46 ± 38.87Changing381.33 ± 251.804-134 ± 17.26-105.46 ± 13.90-131.54 ± 35.45Initial25.92 ± 22.1524.85 ± 2.0626.3 ± 41.2024.7 ± 81.34Final25.99 ± 0.5024.77 ± 2.3025.9 ± 62.0223.9 ± 12.47Changing0.06 ± 2.53-0.08 ± 0.73-0.88 ± 1.84-0.87 ± 2.56Initial22.68 ± 1.7922.25 ± 0.8422.66 ± 1.0822.32 ± 1.48Final24.07 ± 0.7723.35 ± 1.8223.03 ± 1.0122.05 ± 1.87Changing1.60 ± 1.231.10 ± 1.210.37 ± 0.84-0.27 ± 1.17Initial22.00 ± 2.5421.23 ± 2.7720.86 ± 2.9221.99 ± 2.70Final24.07 ± 0.3722.10 ± 1.3022.86 ± 0.9722.84 ± 1.07Changing

RT, radiation therapy; DDP, cisplatin.